UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 21, 2008

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

OXiGENE, Inc.

File No. 0-21990 - CF# 22702

OXiGENE, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K/A filed on October 10, 2008.

Based on representations by OXiGENE, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:

Exhibit 10.1	through October 10, 2013
Exhibit 10.2	through October 10, 2013
Exhibit 10.3	through October 10, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Pamela Howell Special Counsel